Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
Information source: Asociación para Evitar la Ceguera en México
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Macular Edema; Central Retinal Vein Occlusion
Intervention: bevacizumab and triamcinolone (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Asociación para Evitar la Ceguera en México Official(s) and/or principal investigator(s):
Carmen Gonzalez-Mijares, Physician, Principal Investigator, Affiliation: APEC
Hugo Quiroz-Mercado, Retinologyst, Study Director, Affiliation: APEC
Juan Manuel Jimenez Sierra, Retinologyst, Study Chair, Affiliation: APEC
MA Martinez-Castellanos, Physician, Study Chair, Affiliation: APEC
Octavio Burgos Vejar, Physician, Study Chair, Affiliation: APEC
Raul Velez-Montoya, Physician, Study Chair, Affiliation: APEC
Ma de Lourdes Lopez Ramos, Physician, Study Chair, Affiliation: APEC
Omar Honerlager, preresident, Study Chair, Affiliation: APEC
Overall contact:
Carmen Conzalez-Mijares, Physician, Phone: 5517638245, Email: cacegomi@hotmail.com
Summary
Treatment of macular edema secondary to central retinal vein occlusion is more effective with
combined therapy of bevacizumab and triamcinolone than bevacizumab alone.
Clinical Details
Official title: Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion
Study design: Treatment, Randomized, Open Label, Historical Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Changes in Best corrected visual acuity and macular edema measured with OCT
Secondary outcome: Report treatment complications
Detailed description:
Comparison of two groups with different treatment with registrations of outcome in BCVA and
complications
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Macular edema secondary to central retinal vein occlusion
- BCVA worse than 20/40
- Central macular >250 mc with OCT
Exclusion Criteria:
- Diabetic retinopathy or other retinopathy
- Media opacity that does not allow following
- steroid responder
- diagnosed glaucoma or IOP > 21 mmHg
Locations and Contacts
Carmen Conzalez-Mijares, Physician, Phone: 5517638245, Email: cacegomi@hotmail.com
Asociacion Para Evitar la Ceguera en Mexico, Mexico city, Coyoacan 04030, Mexico; Recruiting
Retina Department, Phone: 5510841400, Ext: 1171, Email: retinamex@yahoo.com
Additional Information
Starting date: June 2007
Ending date: March 2008
Last updated: November 30, 2007
|
